7:00 am 
Registration and Breakfast with Exhibitor Experience - Easton B

8:00 am 
What's Going on with FDA— Guidance Documents and Inspections
John Voliva, R.Ph., Executive Vice President
International Academy of Compounding Pharmacists
The FDA inspections and compounding rules have created many questions for compounders. The new Executive Director of IACP will give you the latest information on FDA action, inspections and guidance documents, along with an overview of where USP action is going. If you compound in community or hospital practice, this is an essential session.
At the completion of this activity, the pharmacist/technician participant will be able to:
1. describe the difference between a draft and final FDA Guidance;
2. identify the major deficiencies described in FDA records of inspection (483s); and
3. explain how FDA utilizes Guidances in their regulatory scheme.
UAN: 0129-0000-16-104-P/T  0.1 CEU
This is a knowledge-based activity.

9:00 am 
Sterility Testing of Laboratory Equipment— What Every Compounder Must Know
Kelsey Feathers, CNBT Certified, President
Josh Hatfield, CNBT / NSF Certified, QA Supervisor
Laboratory Certification Services, Inc.
Compounders are required to test and certify that the compounding facility is in compliance. This critical session will give you an overview of testing and certification, and will give you a chance to ask questions. Our speakers are both CNBT (CETA National Board of Testing) Certified, and will help you understand this complex topic.
At the completion of this activity, the pharmacist/technician participant will be able to:
1. identify key points for USP <800>;
2. define Primary Engineering Control (PEC) and list acceptable methods for creating and controlling a defined, sterile environment for pharmaceutical compounding; and
3. discuss important considerations for new or remodeled cleanrooms.
UAN: 0129-0000-16-105-L04-P/T  0.1 CEU
This is a knowledge-based activity.

10:00 am 
Break with Exhibitor Experience - Easton B

10:30 am 
Implementing USP <800>: Critical Information for Compliance
Ken Speidel, R.Ph., BS Pharm, PharmD, FACA, FIACP
Vice President, Compounding Compliance
Gates Healthcare Associates
One of the newest and most misunderstood areas of compounding regulation is USP 800. In this session, you'll gain a clear understanding of what must be done to implement this USP section. Pharmacists in both community and hospital practice will gain valuable information.
At the completion of this activity, the pharmacist/technician participant will be able to:
1. review why standards are necessary to reduce the risks of exposure to hazardous drugs;
2. recall USP <800> compliance requirements for hazardous drug compounding;
3. identify appropriate containment-primary engineering controls used for chemical weighing and non-sterile and aseptic processing;
4. discuss required and advised standard operating procedures and processes;
5. describe workflow changes that may be required when working with hazardous drugs; and
6. define air quality control and monitoring parameters for sterile hazardous drug compounding.
UAN: 0129-0000-16-106-L04-P/T  0.15 CEU
This is a knowledge-based activity.

Sponsored by: MEDISCA

12:00 pm 
Lunch with Exhibitor Experience - Easton B
1:30 pm  **Innovative Compounding for Personalized Health**

*Jim LaValle, R.Ph., C.C.N., Founder*
*Metabolic Code Enterprises, Inc.*

Consumers are moving decidedly in the direction of “quantified health” and want more personalized approaches to support their health goals. Compounding pharmacy provides the ability to target specific formulations based on labs, quality of life and individual preference so the consumer can maximize their health potential. This session will look at novel applications of compounding to target areas such as weight loss, cognitive function and individualized vitamin, mineral and nutrient delivery.

At the completion of this activity, the pharmacist/technician participant will be able to:
1. discuss the application of compounding to develop products to assist in weight loss and cognitive function;
2. describe compounding formulations of value in nutrition and vitamin supplementation;
3. define “quantified health” and how pharmacists can help patients achieve health goals; and
4. discuss novel approaches to provide mineral and nutrient delivery.

**UAN: 0129-0000-16-107-L04-P/T  0.15 CEU**

This is a knowledge-based activity.

3:00 pm  Break - *Easton C, D, E*

3:10 pm  **Is Pharmacy Going to the Dogs? Innovative Veterinary Dosage Forms**

*Tom Wynn, R.Ph., Compounding Consultant*
*Fagron Academy*

The veterinary market is projected to be a 10 billion dollar business by 2018 as reported by the American Animal Hospital Association. There are opportunities for compounding pharmacists to take advantage of this upswing in the market. Foams, tiny tablets, and wound powders offer a vast array of potential for the pharmacist. If you compound for animals or plan to, this session is a must.

At the completion of this activity, the pharmacist/technician participant will be able to:
1. recognize the growth potential in the veterinary compound market;
2. identify obstacles in compounding veterinary dosage forms; and
3. discuss innovative oral and topical options for veterinary use.

**UAN: 0129-0000-16-108-L04-P/T  0.1 CEU**

This is a knowledge-based activity.

4:10 pm  **FDA Inspection… What You Can Expect … Because They Will Come**

*Matthew J. Buderer, R.Ph., FIACP and Dannielle Dombrowski, CPhT, Quality Assurance/Quality Control Compliance Manager*
*Buderer Drug Co.*

“We’re from the FDA and we are here for the week to inspect your pharmacy…” This session will give you a hands-on description of what you should expect from an inspection from a pharmacist who has been through it. You’ll learn what you should have ready to make your inspection go smoothly.

At the completion of this activity, the pharmacist/technician participant will be able to:
1. explain how thorough and complex and FDA inspection can be;
2. discuss challenges in decision making on how to comply with FDA when it conflicts with USP and state law; and
3. describe how to respond to Form 483 Inspectional Observations.

**UAN: 0129-0000-16-109-L04-P/T  0.1 CEU**

This is a knowledge-based activity.

5:10 pm  **Adjournment**
Thank You to the Sponsors and Exhibitors of the

CONTINUING PHARMACY EDUCATION CREDIT

This meeting is targeted to compounding pharmacists and pharmacy technicians. To receive continuing pharmacy education credit, you must attend the entire session, actively participate, and complete the CPE form indicating programs attended, your NABP e-profile ID# and birthdate. Sign, date, and return the CPE form to the OPA staff, or to the OPA office within 30 days of the meeting. CPE credit will be uploaded at the end of October to the CPE Monitor, where CPE statements of credit can be printed. The Ohio Pharmacists Foundation adheres to ACPE Standards regarding industry support of continuing pharmacy education. Disclosure of faculty and commercial support relationships will be made known at the activity. Speakers are expected to openly disclose intent to discuss any off-label or investigational use of drugs, devices, or equipment in their presentations.

The Ohio Pharmacists Foundation, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.